Search research articles
Contact Us
Filters
Showing results (521-530 of 703) with videos related to
Page
of 71
Sort By:
Cancer Discovery
|
January 29, 2014
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis
Tiffany J Parmenter, Margarete Kleinschmidt, Kathryn M Kinross, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
April 16, 2025
Longitudinal Analysis Reveals Dynamic Changes in Histopathologic Features in Responders to Neoadjuvant Treatment in a Stage III BRAF-Mutant Melanoma Cohort
Jorja Braden, Alison Potter, Robert V Rawson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 17, 2020
Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy
Gabriela Marsavela, Jenny Lee, Leslie Calapre, et al.
The Lancet. Oncology
|
October 5, 2015
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
Jean Jacques Grob, Mayur M Amonkar, Boguslawa Karaszewska, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 8, 2025
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study
Jason J Luke, Paolo A Ascierto, Muhammad A Khattak, et al.
The New England Journal of Medicine
|
November 18, 2014
Improved overall survival in melanoma with combined dabrafenib and trametinib
Caroline Robert, Boguslawa Karaszewska, Jacob Schachter, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 28, 2020
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma
Caroline Robert, Wen-Jen Hwu, Omid Hamid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 14, 2022
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> V600-Mutant Unresectable or Metastatic Melanoma
Reinhard Dummer, Georgina V Long, Caroline Robert, et al.
Annals of Surgical Oncology
|
February 1, 2025
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial
Charles H Yoon, Merrick I Ross, Brian R Gastman, et al.
Cell Reports
|
June 30, 2024
Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy
Camelia Quek, Aditya Pratapa, Xinyu Bai, et al.
Page
of 71
Search research articles
Search
Showing results (521-530 of 703) with videos related to
Sort By:
Page
of 71
Cancer Discovery
|
January 29, 2014
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis
Tiffany J Parmenter, Margarete Kleinschmidt, Kathryn M Kinross, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
April 16, 2025
Longitudinal Analysis Reveals Dynamic Changes in Histopathologic Features in Responders to Neoadjuvant Treatment in a Stage III BRAF-Mutant Melanoma Cohort
Jorja Braden, Alison Potter, Robert V Rawson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 17, 2020
Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy
Gabriela Marsavela, Jenny Lee, Leslie Calapre, et al.
The Lancet. Oncology
|
October 5, 2015
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
Jean Jacques Grob, Mayur M Amonkar, Boguslawa Karaszewska, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 8, 2025
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study
Jason J Luke, Paolo A Ascierto, Muhammad A Khattak, et al.
The New England Journal of Medicine
|
November 18, 2014
Improved overall survival in melanoma with combined dabrafenib and trametinib
Caroline Robert, Boguslawa Karaszewska, Jacob Schachter, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 28, 2020
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma
Caroline Robert, Wen-Jen Hwu, Omid Hamid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 14, 2022
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> V600-Mutant Unresectable or Metastatic Melanoma
Reinhard Dummer, Georgina V Long, Caroline Robert, et al.
Annals of Surgical Oncology
|
February 1, 2025
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial
Charles H Yoon, Merrick I Ross, Brian R Gastman, et al.
Cell Reports
|
June 30, 2024
Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy
Camelia Quek, Aditya Pratapa, Xinyu Bai, et al.
Page
of 71